Lisa Zimmermann, the second woman to enroll in a trial of a drug-enhanced therapy made by Nurix Therapeutics, has seen a 47% reduction in her ovarian cancer tumors after treatment and "doctors are hopeful the treatment will continue to work as time passes," according to a feature written by Hanna Webster for the Pittsburgh Post-Gazette. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NRIX:
- Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
- Nurix Therapeutics to Participate in Upcoming Investor Conferences
- Nurix Therapeutics reports case study of patient with aggressive non-GCB DLBCL
- Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit
- Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) Summit